AR062113A1 - Derivados de eteres heterociclicos sustituidos,composiciones farmaceuticas que los contienen y usos en trastornos del cns. - Google Patents

Derivados de eteres heterociclicos sustituidos,composiciones farmaceuticas que los contienen y usos en trastornos del cns.

Info

Publication number
AR062113A1
AR062113A1 ARP070103320A ARP070103320A AR062113A1 AR 062113 A1 AR062113 A1 AR 062113A1 AR P070103320 A ARP070103320 A AR P070103320A AR P070103320 A ARP070103320 A AR P070103320A AR 062113 A1 AR062113 A1 AR 062113A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
halo
cyano
substituted
Prior art date
Application number
ARP070103320A
Other languages
English (en)
Inventor
Michael F Parker
Joanne J Bronson
Mark V Silva
Kevin W Gillman
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR062113A1 publication Critical patent/AR062113A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque tiene la formula 1 en donde: R1 es hidrogeno o alquilo; R2 es hidrogeno o alquilo; R3 es hidrogeno o alquilo; R4 es azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, tiomorfolinilo, o pirrolinilo y está substituido con 0-3 substituyentes seleccionados del grupo que consiste de halo, alquilo, haloalquilo, ciano, amino, alquilamino, dialquilamino, pirrolidinilo, y piperidinilo; R5 es hidrogeno o alquilo; Ar1 es fenilo o piridinilo y está substituido con 0-3 substituyentes seleccionados del grupo que consiste de halo, alquilo, haloalquilo, y ciano; Ar2 es piridinilo o pirimidinilo y está substituido con 0-3 substituyentes seleccionados del grupo que consiste de halo, alquilo, cicloalquilo, (cicloalquil)alquilo, haloalquilo, alcoxi, haloalcoxi, ciano, amino, alquilamino, dialquilamino, R4, y Ar3; y Ar3 es fenilo, piridinilo, furanilo, tienilo, pirrolilo, isoxazolilo, isotiazolilo, pirazolilo, oxazolilo, tiazolilo, imidazolilo, oxadiazolilo, tiadiazolilo, triazolilo, o tetrazolilo y está substituido con 0-3 substituyentes seleccionados del grupo que consiste de halo, alquilo, haloalquilo, alcoxi, haloalcoxi, ciano, y CO2R5; o una sal del mismo farmacéuticamente aceptable.
ARP070103320A 2006-07-27 2007-07-26 Derivados de eteres heterociclicos sustituidos,composiciones farmaceuticas que los contienen y usos en trastornos del cns. AR062113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83365206P 2006-07-27 2006-07-27

Publications (1)

Publication Number Publication Date
AR062113A1 true AR062113A1 (es) 2008-10-15

Family

ID=38895951

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103320A AR062113A1 (es) 2006-07-27 2007-07-26 Derivados de eteres heterociclicos sustituidos,composiciones farmaceuticas que los contienen y usos en trastornos del cns.

Country Status (16)

Country Link
US (1) US20080027056A1 (es)
EP (1) EP2069328A2 (es)
JP (1) JP2009544726A (es)
KR (1) KR20090043497A (es)
CN (1) CN101495470A (es)
AR (1) AR062113A1 (es)
AU (1) AU2007276744A1 (es)
BR (1) BRPI0714615A2 (es)
CA (1) CA2659192A1 (es)
CL (1) CL2007002201A1 (es)
MX (1) MX2009000762A (es)
NO (1) NO20090193L (es)
PE (1) PE20080678A1 (es)
TW (1) TW200817361A (es)
WO (1) WO2008014247A2 (es)
ZA (1) ZA200900613B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
US20090018163A1 (en) * 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US7632861B2 (en) * 2007-11-13 2009-12-15 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009096941A1 (en) * 2008-01-28 2009-08-06 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in cns disorders
SG187286A1 (en) 2011-07-29 2013-02-28 Smart Communications Inc System and method for activating a mobile device to initiate a communication

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678409B2 (en) * 1992-10-28 1997-05-29 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
US7041682B2 (en) * 2002-07-03 2006-05-09 Schering Corporation NK1 antagonists
US20050245572A1 (en) * 2002-09-09 2005-11-03 Peter Bernstein Naphthyl ether compounds and their use
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors

Also Published As

Publication number Publication date
WO2008014247A3 (en) 2008-03-20
BRPI0714615A2 (pt) 2013-06-18
US20080027056A1 (en) 2008-01-31
JP2009544726A (ja) 2009-12-17
KR20090043497A (ko) 2009-05-06
MX2009000762A (es) 2009-01-28
CN101495470A (zh) 2009-07-29
CA2659192A1 (en) 2008-01-31
AU2007276744A1 (en) 2008-01-31
CL2007002201A1 (es) 2008-02-08
EP2069328A2 (en) 2009-06-17
PE20080678A1 (es) 2008-06-26
WO2008014247A2 (en) 2008-01-31
ZA200900613B (en) 2010-04-28
NO20090193L (no) 2009-01-29
TW200817361A (en) 2008-04-16

Similar Documents

Publication Publication Date Title
AR067528A1 (es) Eteres heterociclicos sustituidos y su uso en trastornos del snc
AR073740A1 (es) Compuestos para el tratamiento de la hepatitis c
CR9314A (es) Derivado de espirocetal y uso del mismo como medicina para la diabetes
ES2571327T3 (es) Composiciones plaguicidas
CO6311055A2 (es) Composiciones pesticidas con al menos cuatro estructuras de anillo
AR063707A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
AR073586A1 (es) Compuestos heterociclicos utiles para el tratamiento de vhc
CO5700820A2 (es) Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR062928A1 (es) Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
CO6150090A2 (es) Nuevos derivados de piridazina
TW200738684A (en) Novel sulfated cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
AR062113A1 (es) Derivados de eteres heterociclicos sustituidos,composiciones farmaceuticas que los contienen y usos en trastornos del cns.
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
AR067897A1 (es) Compuestos para el tratamiento de hepatitis c
AR058928A1 (es) Piperazinas y piperidinas como potenciadoras de mglur5. usos y composiciones farmaceuticas.
AR060496A1 (es) Inhibidores transportadores de serotonina y nk-1
TW200626605A (en) Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal